CBA Florida, Inc. - FORM 10-Q

Attached files

file	filename
EX-31.1 - CERTIFICATION - CBA Florida, Inc.	cbai_ex311.htm
EX-31.2 - CERTIFICATION - CBA Florida, Inc.	cbai_ex312.htm
EX-10.10 - LICENSE AGREEMENT - CBA Florida, Inc.	cbai_ex1010.htm
EX-32.1 - CERTIFICATION - CBA Florida, Inc.	cbai_ex321.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2010

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

for the transition period from _________ to _________

CORD BLOOD AMERICA, INC.

(Exact Name of Small Business Registrant as Specified in its Charter)

FLORIDA		000-50746		65-1078768
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1857 HELM DRIVE LAS VEGAS, NV 89119		89119
(Address of principal executive offices)		(Zip Code)

(702) 914-7250

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all documents and reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company filer

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act.): Yes ¨ No þ

Number of shares of Cord Blood America, Inc. common stock, $0.0001 par value, outstanding as of May 12, 2010: 5,078,235,011, exclusive of treasury shares.

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

	PART I. FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets (unaudited) as of March 31, 2010 and December 31, 2009 (audited)	2

	Condensed Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2010 and 2009	3

	Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2010 and 2009	4

	Notes to Condensed Financial Statements (unaudited)	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4T.	Controls and Procedures	17

	PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	18

Item 2.	Unregistered Sales Of Equity Securities And Use Of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Reserved	18

Item 5.	Other Information	18

Item 6.	Exhibits And Reports On Form 8-K	18

Signatures		19

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2010 (UNAUDITED) AND DECEMBER 31, 2009

ASSETS
Current assets:	March 31, 2010			December 31, 2009
Cash	$	836,186		$	716,576
Accounts receivable, net of allowance for doubtful accounts of $70,000		319,144			174,103
Investments and related party receivable		208,474			––
Prepaid expenses		7,424			––
Total current assets		1,371,228			890,679
Property and equipment, net of accumulated depreciation and amortization of $167,551 and $146,888		509,467			383,597
Other current assets		400			––
Customer contracts and relationships, net of accumulated amortization of $1,601,147 and $1,477,399		3,724,571			3,848,319
Other assets		149,036			––
Total assets	$	5,754,702		$	5,122,595
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Deferred Rent	$	214,424		$	––
Accounts payable		973,192			709,519
Accrued expenses		596,114			380,543
Deferred revenue		1,627,480			1,475,261
Advances from officers		7,810			29,229
Derivative liability		2,154,986			2,405,553
Promissory notes payable, net of unamortized discount of $372,214 and $83,784		1,135,368			161,886
Total current liabilities		6,709,374			5,161,991
Commitments and contingencies, note 5
Stockholders’ deficit:
Preferred stock, $.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding		––			––
Common stock, $.0001 par value, 6,950,000,000 shares authorized, 5,078,235,011 and 4,947,735,145 shares issued and outstanding, inclusive of treasury shares		507,824			494,774
Additional paid-in capital		36,413,824			34,763,094
Common stock held in treasury stock, 2,000,000 shares		(599,833	)		(599,833	)
Accumulated deficit		(37,276,487	)		(34,697,431	)
Total stockholders’ deficit		(954,672)			(39,396	)
Total liabilities and stockholders’ deficit	$	5,754,702		$	5,122,595

See the accompanying notes to condensed consolidated financial statements.

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009

	THREE-MONTH PERIOD			THREE-MONTH PERIOD
	ENDED			ENDED
	MARCH 31,			MARCH 31,
	2010			2009
Revenue	$	839,343		$	941,938
Cost of services		(415,366	)		(447,514	)
Gross profit		423,977			494,424
Administrative and selling expenses		(1,750,262	)		(803,323	)
Start-up Costs		(820,471	)		––
Loss from operations		(2,146,756	)		(308,899	)
Interest expense and change in derivative liability		(432,071	)		(1,414,378	)
Net loss before income taxes		(2,578,827	)		(1,723,277	)
Income taxes		––			––
Net loss		(2,578,827	)		(1,723,277	)
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)
Weighted average common shares outstanding		5,055,188,615			821,575,972

See the accompanying notes to condensed consolidated financial statements.

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR

THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009

	THREE-MONTH			THREE-MONTH
	PERIOD ENDED			PERIOD ENDED
	MARCH 31,			MARCH 31,
	2010			2009
Cash flows from operating activities:
Net loss	$	(2,578,827	)	$	(1,723,277	)
Adjustments to reconcile net loss to net cash used in operating activities:

Issuance of stock for services		427,300			151,910
Shares issued to employees, directors, and consultants		30,000			––
Amortization of loan discount		32,700			253,557
Amortization of deferred financing costs		––			578,662
Depreciation and amortization		144,411			167,690
Change in value of derivative liability		(5,373	)		(4,136	)
Share based compensation		551,603			––
Start-up costs for stellacure		820,471			––
Shares and warrants issued for financing		––			204,419
Net change in operating assets and liabilities		(544,456	)		270,216
Net cash used in operating activities		(1,122,171	)		(100,959	)

Cash flows from investing activities:
Payments for purchase of property and equipment		(86,800	)		––

Net cash used in investing activities		(86,800	)		––

Cash flows from financing activities:
Bank overdraft		––			(17,083	)
Issuance of common shares for cash		150,000			347,486
Proceeds from issuance of notes payable		1,200,000			––
Payments on notes payable		––			(104,240	)
Proceeds from advances from shareholders		––			2,944
Payments on advances from shareholders		(21,419	)		(18,676	)
Payments on capital lease obligations		––			(2,589	)
Net cash provided by financing activities		1,328,581			207,842

Net increase in cash		119,610			106,883
Cash and cash equivalents, at beginning of period		716,576			––
Cash and cash equivalents, at end of period	$	836,186		$	106,883

See the accompanying notes to condensed consolidated financial statements.

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLDIATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR

THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009

	THREE-MONTH PERIOD		THREE-MONTH PERIOD
	ENDED		ENDED
	MARCH 31,		MARCH 31,
	2010		2009
Supplemental disclosures:
Cash paid for interest	$	––	$	50,762

Supplemental disclosures of non-cash investing and financing activities:

Debt repaid through issuance of common stock	$	38,819	$	1,532,234

See the accompanying notes to condensed consolidated financial statements.

CORD BLOOD AMERICA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2010

Note 1. Organization and Description of Business

Cord Blood America, Inc. ("CBAI"), formerly D&A Lending, Inc., was incorporated in the State of Florida on October 12, 1999. In October, 2009, CBAI re-located its headquarters from Los Angeles, California to Las Vegas, Nevada. CBAI is primarily a holding company whose wholly-owned subsidiaries include Cord Partners, Inc., CorCell Co. Inc., CorCell Ltd., (“Cord”), CBA Professional Services, Inc. D/B/A BodyCells, Inc. ("BodyCells"), CBA Properties, Inc. ("Properties"), and Career Channel Inc, D/B/A Rainmakers International ("Rain"). In March 2010, CBAI purchased a majority interest in stellacure GmbH. CBAI and its subsidiaries engage in the following business activities:

·	Cord specializes in providing private cord blood stem cell preservation services to families.

·	stellacure GmbH specializes in providing cord blood stem cell preservation services to families in Germany and Spain.

·	BodyCells is a developmental stage company and intends to be in the business of collecting, processing and preserving peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy.

·	Properties was formed to hold the corporate trademarks and other intellectual property of CBAI.

·	Rain specializes in creating direct response television and radio advertising campaigns, including media placement and commercial production.

The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements of Cord Blood America, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The condensed financial statements reflect all normal recurring adjustments, which, in the opinion of management, are considered necessary for a fair presentation of the results for the periods shown. The results of operations for the periods presented are not necessarily indicative of the results expected for the full fiscal year or for any future period. The information included in these unaudited condensed financial statements should be read in conjunction with Management's Discussion and Analysis and Plan of Operations contained in this report and the audited condensed financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

Basis of Consolidation

The condensed financial statements include the accounts of CBAI and its wholly-owned and majority-owned subsidiaries, Cord, stellacure GmbH, BodyCells, Properties and Rain. All significant inter-company balances and transactions have been eliminated upon consolidation.

Deferred Revenue

Deferred revenue for Cord consists of payments for enrollment in the program and processing of umbilical cord blood by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

Valuation of Derivative Instruments

ASC 815-40 (formerly SFAS No. 133 "Accounting for derivative instruments and hedging activities"), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF 00-19 "Accounting for derivative financial instruments indexed to, and potentially settled in, a company's own stock") to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula. At March 31, 2010, the Company adjusted its derivative liability to its fair value, and reflected the decrease in fair value, in its statement of operations.

Revenue Recognition

CBAI recognizes revenue under the provisions of ASC 605-25 (previously Staff Accounting Bulletin 104 “Revenue Recognition”). Cord provides a combination of products and services to customers. This combination arrangement is evaluated under ASC 605-25-25 (previously Emerging Issues Task Force Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables"). ASC 605-25-25 addresses certain aspects of accounting for arrangements under multiple revenue generating activities.

Cord recognizes revenue from both enrollment fees and processing fees upon the completion of processing while storage fees are recognized ratably over the contractual storage period.

Rain generates revenue from packaged advertising services, including media buying, on-hold and motor sports advertising campaigns, marketing and advertising production services. Rain's advertising service revenue is recognized when the media ad space is sold and the advertising occurs. Rain's advertising production service revenue is derived through the production of an advertising campaign including, but not limited to, audio and video production, establishment of a target market and the development of an advertising campaign. Rain recognizes revenue generated from packaged advertising services provided to our clients using the "Gross" basis of ASC 605-45 (formerly Emerging Issues Task Force No. 99-19, "Reporting Revenue Gross as a Principal versus Net as an Agent)".

Rain's revenue recognition policy involves significant judgments and estimates about the ability to collect. We assess the probability of collection based on a number of factors, including past transaction history and/or the creditworthiness of our clients' customers, which is based on current published credit ratings, current events and circumstances regarding the business of our client's customer and other factors that we believe are relevant. If we determine that collection is not reasonably assured, we defer revenue recognition until such time as collection becomes reasonably assured, which is generally upon receipt of cash payment. Rain recognizes revenue generated through per inquiry advertising as the per inquiry leads are delivered to the customer.

Cost of Services

Costs for Cord are incurred as umbilical cord blood is collected. These costs include the transportation of the umbilical cord blood from the hospital to the lab, the labs’ processing fees, and royalties. The Company expenses costs in the period incurred. Costs for Rain include commercial production costs, lead generation costs and media buys.

Fair Value Measurements

CBAI measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date. The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs, as defined by ASC 820-10, are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2010 for assets and liabilities measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3			Total
Cash and cash equivalents	$	836,186	$	—	$	—		$	836,186

Derivative liability		—		—		(2,154,986	)		(2,154,986	)

Derivative liability was valued under the Black-Scholes model, consistent with last year, with the following assumptions:

Risk free interest rate		0.24% to 1.60%
Expected life		0 to 4 years
Dividend Yield		0%
Volatility		0% to 165%

The following is a reconciliation of the derivative liability:

Value at December 31, 2009	$	2,405,553
Issuance of instruments		221,030
Decrease in Value		(5,373	)
Reclassification to equity		(466,224	)
Value at March 31, 2010	$	2,154,986

Net Loss Per Share

Net loss per common share is calculated in accordance with ASC 260. Basic net loss per share is computed by dividing the net loss by the weighted average common shares outstanding. Outstanding options to acquire common stock and warrants are not included in the computation of diluted net loss per share because the effects of inclusion are anti-dilutive.

Recent Accounting Pronouncements

In June 2009, the FASB amended ASC 860, (formerly SFAS No. 166, Accounting for Transfers of Financial Assets, an amendment to SFAS No. 140). ASC 860 eliminates the concept of a “qualifying special-purpose entity,” changes the requirements for derecognizing financial assets, and requires additional disclosures in order to enhance information reported to users of financial statements by providing greater transparency about transfers of financial assets, including securitization transactions, and an entity’s continuing involvement in and exposure to the risks related to transferred financial assets. ASC 860 is effective for fiscal years beginning after November 15, 2009. The adoption of ASC 860 did not have a material impact on our condensed financial statements.

In June 2009, the FASB amended ASC 810 (formerly Statement of Financial Accounting Standards No.167, Amendments to FASB Interpretation No. 46(R)). The amendments include: (1) the elimination of the exemption for qualifying special purpose entities, (2) a new approach for determining who should consolidate a variable-interest entity, and (3) changes to when it is necessary to reassess who should consolidate a variable-interest entity. ASC 810 is effective for the first annual reporting period beginning after November 15, 2009 and for interim periods within that first annual reporting period. The adoption of ASC 810 did not have a material impact on our financial statements.

In August 2009, the FASB issued ASU 2009-15, which changes the fair value accounting for liabilities. These changes clarify existing guidance that in circumstances in which a quoted price in an active market for the identical liability is not available, an entity is required to measure fair value using either a valuation technique that uses a quoted price of either a similar liability or a quoted price of an identical or similar liability when traded as an asset, or another valuation technique that is consistent with the principles of fair value measurements, such as an income approach (e.g., present value technique). This guidance also states that both a quoted price in an active market for the identical liability and a quoted price for the identical liability when traded as an asset in an active market when no adjustments to the quoted price of the asset are required are Level 1 input fair value measurements. This ASU became effective for us on January 1, 2010. Adoption of this ASU did not have a material impact on our condensed financial statements.

In January, 2010, the FASB issued ASU 2010-06, Improving Disclosures about Fair Value Measurements. The standard amends ASC Topic 820, Fair Value Measurements and Disclosures to require additional disclosures related to transfers between levels in the hierarchy of fair value measurement. The standard does not change how fair values are measured. The standard is effective for interim and annual reporting periods beginning after December 15, 2009. The adoption of ASU 2010-06 did not have a material impact on our condensed its financial statements.

Note 3. Summary of Acquisition

In March 2010, the Company acquired 138,712 Series B Shares of stellacure, GmbH, which represents an ownership percentage of 51%, a German Limited Liability Company that is in the business of collecting, processing, and storing cord blood samples. The purchase price paid by the Company was EUR 501,000. stellacure operates primarily in Germany, however, it established sales channels in Spain and Italy in 2009. The Company intends to utilize these markets for immediate market penetration and an opportunity for growth throughout Europe.

In connection with the acquisition, the Company acquired the following assets and liabilities:

Cash	$	466,735
Accounts receivable		183,274
Investments and other receivables		208,474
Prepaid expenses		7,424
Property and equipment**		59,733
Other assets		149,036
Total Assets	$	1,074,676

Accounts payable	$	406,115
Accrued expenses		334,994
Deferred revenue		206,862
Total Liabilities	$	947,971

**The carrying amount of the property and equipment acquired was reduced by $7,431 to adjust it to its fair market value on the date of acquisition.

Except for the property and equipment identified above, the Company believes that the carrying amount of the assets and liabilities acquired approximate their respective fair values. Given that stellacure has operated at a loss for the past several years, has negative working capital as of the acquisition date, and has a limited operating history, the Company determined that the fair value of any intangible assets identified as well as the non-controlling interest was $0. As such, the Company recorded a charge of $820,471 to its condensed statement of operations relating to the acquisition because the costs incurred in the acquisition were akin to a startup cost for the Company’s expansion into Europe.

The results of operations and earnings of stellacure have not been included in the Company’s statement of operations for the period ended March 31, 2010 as the acquisition occurred at the end of the reporting period.

In connection with the purchase of the shares of stellacure, the Company entered into a commitment to purchase the shares of stellacure from the remaining holders, at the option of the holders, in either cash, shares of the Company, or a combination of both. The commitment price is defined in the shareholder agreement and is based on a multiple of the earnings of stellacure. Should the Company pay the commitment price in shares of its common stock, it is required under the agreement that the holders be given stock equal to 110% of the commitment price. The commitment commences in 2012 and expires in 2014. The Company valued this commitment as of March 31, 2010, based on the recent earnings activity of stellacure, and determined that the value of the commitment was $0.

Note 4. Notes and Loans Payable

At March 31, 2010 and December 31, 2009, notes and loans payable consist of:

	March 31, 2010			December 31, 2009
0% Convertible Debenture payable to Enable Capital, effective interest rate of 72% per annum (considering the loan discount), due July 31, 2010	$	––		$	38,189
Convertible Promissory Note Payable to JMJ Financial, secured by $1.3 million of the Company’s assets, one-time interest charge of 10.38%, due May 5, 2012		57,482			57,482
Convertible Promissory Note Payable to JMJ Financial, secured by $1.05 million of the Company's assets, one-time interest charge of 10.50%, due October 26, 2012		900,000			150,000
Convertible Promissory Note Payable to JMJ Financial, secured by $1.5 million of the Company's assets, one time interest charge of 10.33%, due January 19, 2013		250,050			––
Convertible Promissory Note Payable to JMJ Financial, secured by $1.5 million of the Company's assets, one time interest charge of 10.33%, due January 14, 2013		300,050			––
		1,507,582			245,671
Less: Unamortized Discount		( 372,214	)		(83,785	)
	$	1,135,368		$	161,886

Note 5. Commitments and Contingencies

On July 2, 2009, the Company executed a Preferred Stock Purchase Agreement with Optimus Capital Partners, LLC pursuant to which it has secured a $7.5 million capital commitment which may be drawn down in increments, under certain conditions. On November 2, 2009, the Company filed its registration statement for these shares.

Agreements

Pharmastem - In March 2004, Cord entered into a Patent License Agreement with the holder of patents utilized in the collection, processing, and storage of umbilical cord blood to settle litigation against Cord for alleged patent infringements. The Patent License Agreement calls for royalties of 15% of processing and storage revenue, with a minimum royalty of $225 per specimen collected, on all specimens collected after January 1, 2004 until the patents expire in 2010.

Employment Agreements

On July 16, 2008, CBAI entered into a three-year agreement with Mr. Schissler, which is renewable annually thereafter, which provides for a base salary of $165,000 the first year, with five percent automatic base salary increases for each successive year. It also provides for an annual bonus, payable at the discretion of the Board of Directors, equal to thirty percent of the Employee’s prior year base salary. It also provided him with the immediate issuance of 7,500,000, five-year options to acquire restricted shares of the Company’s common shares at an exercise price of $0.01 per share, These options vest twenty-five percent immediately, and twenty-five percent annually thereafter. It also provided Mr. Schissler with the payment of an inducement bonus of 1,000,000 restricted shares of the Company’s common shares. In July, 2009, as a bonus for current and past services rendered, the Company awarded 241,096,000 options to purchase common stock, 50% which vested immediately and the other 120,548,000 to be vested over the next four years. Mr. Schissler is subject to non-competition and confidentiality requirements. CBAI may terminate Mr. Schissler's Executive Agreement at any time without cause. In such event, no later than the Termination Date specified in the Termination Notice (both as defined in the Executive Agreement), CBAI shall pay to Mr. Schissler an amount in cash equal to the sum of his Compensation determined as of the date of such Termination Notice through the remaining term of the Executive Agreement. In December, 2009, Mr. Schissler was awarded a further 242,929,000 options to purchase common stock, 50% which vested immediately and the other 121,464,500 which will vest at December 31, 2010.

On July 16, 2008, CBAI entered into a three-year agreement with Mr. Joe Vicente, who serves as the Company’s Chief Operating Officer, which is renewable annually thereafter, which provides for a base salary of $115,000 the first year, with five percent automatic base salary increases for each successive year. It also provides for an annual bonus, payable at the discretion of the Board of Directors, equal to twenty-five percent of the Employee’s prior year base salary. It also provided him with the immediate issuance of 7,500,000, five-year options to acquire restricted shares of the Company’s common shares at an exercise price of $0.01 per share, These options vest twenty-five percent immediately, and twenty-five percent annually thereafter. It also provided Mr. Vicente with the payment of an inducement bonus of 1,000,000 restricted shares of the Company’s common shares. In July, 2009, as a bonus for current and past services rendered, the Company awarded 120,548,000 options to purchase common stock, 50% which vested immediately and the other 60,274,000 to be vested over the next four years. In December, 2009, Mr. Vicente was awarded a further 121,464,500 options to purchase common stock, 50% which vested immediately and the other 60,732,250 which will vest at December 31, 2010.

Operating Lease

CBAI leases office space which expires at various times through 2014. The lease for the facility in Las Vegas has two options to renew for an additional five years each, extending the term to 2024. Commitments for minimum future rental payments, by year and in the aggregate, to be paid under the operating leases as of March 31, 2010, are as follows:

2010		114,720
2011		275,569
2012		251,139
2013		154,082
2014		118,142
	$	913,652

Note 6. Related Party Transactions and Commitments

Advances from Officers

In prior years, the Company received non-interest bearing advances from officers of CBAI. In addition, on May 11, 2007, Ms. Stephanie Schissler, CBAI's former President and Chief Operating Officer, who is the spouse of the Company's Chief Executive Officer, loaned $121,500 to the Company, to be repaid in 36 equal monthly installments of $3,908. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At March 31, 2010, the balance remaining on this loan was $2,900.

On June 14, 2007, Mr. Matt Schissler, the Company’s Chief Operating Officer, loaned $25,650 to the Company, to be repaid in 36 equal monthly installments of $828. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At March 31, 2010, the balance remaining on this loan was $1,227.

On June 14, 2007, Ms. Stephanie Schissler further loaned $76,950 to the Company, to be repaid in 36 equal monthly installments of $2,483. The Company signed a Promissory Note, which carries interest at the rate of 10% per annum. At March 31, 2010, the balance remaining on this loan was $3,683.

Consulting Agreement

On July 1, 2008, CBAI entered into a one-year consulting agreement with Pyrenees Capital, LLC., a business owned by Stephanie Schissler, CBAI's former President and Chief Operating Officer. Ms. Schissler is the spouse of the Company's Chief Executive Officer. The agreement entitles Ms. Schissler to a monthly retainer and stock option incentives for her services in relation to strategic corporate planning and other business related matters. On January 1, 2010 the agreement was renewed for another 12 months with a retainer of $12,500 per month. The agreement automatically renews for a further term of six months, unless a 60-day written notice of cancellation is provided by Pyrenees Capital, or a 180-day written notice is provided by CBAI.

Note 7. Share Based Compensation

Stock Option Plan

The Company's Stock Option Plan permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 8.0 million shares of its common stock. The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company. On July 13, 2009, the Company registered its 2009 Flexible Stock Plan, which increases the total shares available to 400 million common shares. The agreement allows the Company to issue either stock options or common shares from this Plan.

The Company awarded a total of 20 million options to purchase common shares to Stephanie Schissler, to compensate her for both past services and future services.

Stock options that vest at the end of a one-year period are amortized over the vesting period using the straight-line method. For stock options awarded using graded vesting, the expense is recorded at the beginning of each year in which a percentage of the options vests.

The Company’s stock option activity was as follows:

	Stock Options		Weighted Average Exercise Price		Weighted Avg. Contractural Remaining Life
Outstanding, January 1, 2009		22,308,140		0.07		5.5
Granted		725,965,000		0.01
Exercised		-
Forfeited/Expired		-
Outstanding, December 31, 2009		749,273,140		0.01		7.3
Granted		20,000,000		0.01
Exercised		-
Forfeited/Expired		-
Outstanding, March 31, 2010		769,273,140		0.01		7.39
Exercisable at March 31, 2010		376,879,390		0.01		7.4

A summary of the activity for unvested employee stock options as of March 31, 2010, and changes during the year is presented below:

	Stock Options		Weighted Average Grant Date Fair Value per Share

Non-vested at January 1, 2010		372,393,750	$	0.01
Granted		20,000,000		0.01
Vested		0	$	0.0
Forfeited		0		––
Non-vested at March 31, 2010		392,393,750	$	0.01

The following table summarizes significant ranges of outstanding stock options under the stock option plan at March 31, 2010:

Range of Exercise Prices		Number of Options	Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number of Options Exercisable	Weighted Average Exercise Price
$	0.0033 — 0.20	764,470,692		7.40	$	0.010	372,076,942	$	0.010
$	0.21 — 0.30	3,012,600		4.87		0.250	3,012,600		0.250
$	0.31 — 0.51	1,789,848		5.69		0.312	1,789,848		0.312
		769,273,140		7.39	$	0.009	376,879,390	$	0.191

Note 8. Warrant Agreements

On July 2, 2009, the Company executed a Preferred Stock Purchase Agreement with Optimus Capital Partners, LLC, which also entitled them to a five-year conditional warrant to purchase 1,446,428,571 of the Company’s Common Stock at $0.007 per share.

On June 23, 2009, the Company issued a Promissory Note for $200,000 along with 54,200,542 three-year warrants at $0.0037 per share.

On January 30, 2009, Enable Capital, a warrant holder, exercised their right to purchase 31,449,102 shares of the Company’s Common Stock at $0.0086 per share.

On October 10, 2009, Cornell, a warrant holder, exercised their right to purchase 1,263,920 shares of the Company's Common Stock at $0.35 per share, on a cashless basis.

On January 14, 2010, Schottland, a warrant holder, exercised their right to purchase 42,771,971 shares of the company's Common Stock at $0.0037 per share, on a cashless basis.

The following table summarizes the warrants outstanding and exercisable at March 31, 2010:

WARRANTS OUTSTANDING		EXERCISE PRICE			MATURITY DATE
	15,729,730		$	0.101	02/14/2012
	4,000,000		$	0.101	02/14/2012
	2,916,667		$	0.037	11/26/2012
	3,796,950		$	0.037	05/15/2013
	9,655,531		$	0.0086	05/30/2013
	11,428,571		$	0.037	06/23/2012
Total 47,527,449

Note 9. Stockholder’s Equity

Preferred Stock

CBAI has 5,000,000 shares of $.0001 par value preferred stock authorized. On July 2, 2009, the Company executed a Preferred Stock Purchase Agreement with Optimus Capital Partners, LLC, pursuant to which it has secured a $7.5 million capital commitment which may be drawn down in increments through the “put” to the Fund of newly issued Series A Preferred Stock, subject to meeting certain conditions.

Up to 750 shares of Series A Preferred stock, par value $0.0001, may be “put” to the Fund at a purchase price of $10,000 per share over a period of time. The Series A Preferred stock accrues dividends at the rate of 10% be annum, precludes other dividends until it is paid, and has a liquidation preference equal to $10,000 plus all accrued but unpaid dividends. The Series A Preferred is redeemable after four years at a redemption price of equal to $10,000 plus all accrued but unpaid dividends (or earlier if certain additional premiums are paid). The Series A Preferred Stock will not be publicly traded.

Common Stock

On March 25, 2009, the Company’s Articles of Incorporation were amended to increase the authorized common stock to 6,945,000,000 shares, par value $0.0001, up from 950,000,000. This amendment was adopted by the Company’s Board of Directors on February 12, 2009, and its Shareholders at a Special Meeting of Shareholders called for this purpose on March 23, 2009.

During the first three months ending March 31, 2010, a warrant holder exercised a portion of their warrants, or 42,771,971 shares at an exercise price of $0.0037, exercised on a cashless basis.

As of March 31, 2010 CBAI had 5,078,235,011 shares of Common Stock outstanding. 2,000,000 shares remain in the Company's treasury.

Note 10. Segment Reporting

Guidance issued by the FASB requires that public business enterprises report financial and descriptive information about its reportable operating segments. CBAI has two operating segments. Cord generates revenues related to the processing and preservation of umbilical cord blood. Rain generates revenues related to television and radio advertising. All of its long-lived assets are located in, and substantially all of its revenues are generated from within, the United States of America.

The table below presents certain financial information by business segment for the three months ended March 31, 2010:

						Radio/
	Umbilical					Television		Segment						Condensed
	Cord Blood			stellacure		Advertising		Total			Eliminations			Total
Revenue from External Customers	$	839,343		$	-	$	-	$	839,343					$	839,343
Interest Expense		432,071			-		-		432,071						432,071
Depreciation and Amortization		144,411			-		-		144,411						144,411
Segment Income (Loss)		(2,578,827	)		-		-		(2,578,827	)					(25,788,272	)
Segment Assets	$	5,627,206		$	1,074,672		-	$	6,701,878		$	(947,176	)	$	5,754,702

The table below presents certain financial information by business segment for the three months ended March 31, 2009:

					Radio/
	Umbilical				Television			Segments				Condensed
	Cord Blood				Advertising			Total				Total
Revenue from External Customers		$	773,453			$	168,485		$	941,938			$	941,938
Interest Expense			1,414,378				0			1,414,378				1,414,378
Depreciation and Amortization			167,690				0			167,690				167,690
Segment Income (Loss)			(1,744,4214	)			21,144			(1,723,2774	)			(1,723,2774	)
Segment Assets		$	4,558,533			$	26,313		$	4,584,846			$	4,584,846

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS

Forward Looking Statements

In addition to the historical information contained herein, we make statements in this Quarterly Report on Form 10-Q that are forward-looking statements. Sometimes these statements will contain words such as "believes," "expects," "intends," "should," "will," "plans," and other similar words. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, to obtain additional working capital, and to obtain additional cord blood banking revenue streams. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties.

The following information should be read in conjunction with our March 31, 2010 condensed financial statements and related notes thereto included elsewhere in the quarterly report and with our condensed financial statements and notes thereto for the year ended December 31, 2009 and the related "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in our annual Report on Form 10-K for the year ended December 31, 2009, as well as our quarterly reports and reports filed on Form 8-K for the relevant periods. We also urge you to review and consider our disclosures describing various risks that may affect our business, which are set forth under the heading "Risk Factors Related to our Business" in our annual Report on Form 10-K for the year ended December 31, 2009.

Developments During The Quarter

On January 22, 2010, we officially opened our new facility. On March 1, 2010, we commenced processing cord blood at this new facility and on March 8, 2010, our cryogenic freezers arrived at our facility, which allows us to store cord blood specimens in our own facility. On February 8, 2010, we announced the finalization of an agreement to process and store cord blood specimens for BioCells, Inc., headquartered in Argentina, and expect that activity to commence in the second quarter of 2010. We intend to continue our organic growth through continued improvement of internal processes, continued improvement and expansion of our relationships with health insurance providers, and leveraging those relationships in the pregnancy programs with those providers. We expect to experience limited activity with expanded print, direct response and internet marketing mediums to facilitate increased prospective customer contact. We will be concentrating our efforts on building additional sales channels through obstetrics and gynecological practices and other healthcare professionals, hospitals and other health care influencers. We also hope to leverage our growth through mergers and/or acquisitions of other stem cell preservation companies. We are currently exploring various acquisition opportunities and will continue to do so. We intend to continue to fund mergers and acquisitions to the extent that we identify opportunities and are able to obtain capital on reasonable terms for this purpose from placements of equity, debt and/or convertible debt.

On March 24, 2010, the Company acquired 138,712 Series B Shares (the Shares) in stellacure GmbH, a German Limited Liability Company which is in the business of collecting, processing and storing cord blood samples as a private bank for use in current or future medical therapies in Germany, Spain, and other European and Middle Eastern Countries. The shares represent 51% of the total outstanding shares of stellacure.

Cord Blood believes this acquisition may serve as a strategic footprint into the growth of the stem cell business throughout Europe. In addition to Germany which stellacure started processing and storing in 2006, additional stellacure sales channels established in 2009 in Spain and Italy provide immediate market penetration and an opportunity for growth. Cord Blood management intends to continue to pursue additional sales channels in other markets in 2010, to the extent capital is available for this purpose. Cord Blood views the established relationship stellacure has with the German Red Cross as a potential catalyst for expansion of Cord Blood services throughout Europe.

In March of 2010, the Company entered into a License Agreement with AXM Pharma, Inc., whose China subsidiary is establishing a Stem Cell collection and storage service in China. The initial term of the Agreement is five years, and provides for the sharing by the Company of its knowhow and expertise as well as support and training, in exchange for payment to the Company of a royalty equal to 8.5% of net revenues from the stem cell collection and storage business generated in China, and a 10% equity interest in AXM Pharma, Inc.’s operating China Subsidiary.

Summary and Outlook of the Business

CBAI is primarily an umbilical cord blood stem cell preservation company with a particular focus on the acquisition of customers in need of family based products and services. We also have limited operations providing television and radio advertising services to businesses that sell family based products and services.

Thus, we operate a primary core business and a secondary business:

·	Cord operates the umbilical cord blood stem cell preservation operations, and

·	Rain has limited operations providing television and radio advertising services.

Cord

The umbilical cord blood stem cell preservation operations provide umbilical cord blood banking services to expectant parents throughout all 50 United States. Our corporate headquarters recently re-located to Las Vegas, NV from Los Angeles, CA. Cord earns revenue through a one-time enrollment and processing fee, and through an annually recurring storage and maintenance fee. Cord blood testing, processing, and some storage was conducted by our outsourced laboratory partner, Progenitor Cell Therapy, LLC, (PCT) in New Jersey. In March 2010, we began to process and store cord blood in our own facility, terminating our contract with PCT on February 28, 2010, and now provide in house all our own processing and storage services. We provide the following services to each customer.

●	Collection Materials. We provide a medical kit that contains all of the materials necessary for collecting the newborn’s umbilical cord blood at birth and packaging the unit for transportation. The kit also provides for collecting a maternal blood sample for later testing.

●	Physician And Customer Support. We provide 24-hour consulting services to customers as well as to physicians and labor and delivery personnel, providing any instruction necessary for the successful collection, packaging, and transportation of the cord blood & maternal blood samples.

●	Transportation. We coordinate the transportation of the cord blood unit to our laboratory partner, Progenitor Cell Therapies, immediately following birth. This process utilizes a private medical courier, AirNet, for maximum efficiency and security.

●	Comprehensive Testing. At the laboratory, the cord blood sample is tested for stem cell concentration levels, bacteria and blood type. The maternal blood sample is tested for infectious diseases. We report these results to the newborn’s mother.

●

Cord Blood Preservation. After processing and testing, the cord blood unit is cryogenically frozen in a controlled manner and stored in liquid nitrogen for potential future use in our own storage facility. Data indicates that cord blood retains viability and function for at least fifteen years when stored in this manner and theoretically could be maintained at least as long as the normal life span of an individual.

Going forward, management will continue to assess business opportunities, and plans to pursue customer acquisition, both through organic growth and acquisition provided sources of capital are available.

Rain

Rain has specialized in creating direct response television and radio advertising campaigns, including media placement and commercial production. Management has reduced the activities of Rain, terminated its former employees, and by the end of 2009, the subsidiary was maintaining only a modest presence on the internet, continuing to accept business which was proffered to it, but no longer aggressively seeking business. This is consistent with management’s decision to focus its attention on the stem cell storage business and related activities as the Company’s core business.

BodyCells

We are continuing to pursue other growth opportunities by acquisition or internal growth. The development of BodyCells, which is anticipated to facilitate the collecting, processing and preserving of peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy, is currently suspended pending the identification of an alternative lab to partner.

Results of Operations for the Three-Months Ended March 31, 2010

For the three months ended March 31, 2010, our total revenue decreased approximately $0.1 million, or 11% to approximately $0.8 million. The decrease in revenue was a result of the drop in Rain's revenue. Rain’s revenues decreased approximately $0.2 million due in part to the steep down turn in the economy, due to the change in the Rain business model, and because of our decision to de-emphasize Rain's business. Cord’s revenues increased approximately $0.05 million to approximately $0.8 million due to an increase in customer base. Our total annual storage fees increased approximately $0.4 million to approximately $0.8 million. Cord remains focused on strategic organic growth and accretive acquisition strategies, which management hopes will reduce or eliminate the losses and negative operating cash flow. Management believes it will be able to obtain the additional capital, be it debt, equity, convertible debt or a combination thereof on commercially reasonable terms, necessary to sustain such effort, but there is no assurance that the Company will be successful in this regard.

Cost of services decreased by approximately 7% to $0.4 million, and Gross Profit decreased from 52% of revenues to 51%. The decrease in cost of services is due to bringing the lab processing and storage in house. The company believes that through the growth and expansion of our Cord business, and the processing and storage of the cord blood in our own facilities, our direct costs may decrease and our gross margins increase.

Administrative and selling expenses increased by approximately $0.9 million, or 118% from the prior comparative period to $1.8 million. During the quarter, the Company had stock option non-cash expense of $0.5 million. The Company spent $0.65 million to purchase stellacure, a company in Germany, which allowed Cord to enter the European market. The acquisition of stellacure has resulted in start-up costs of $0.8 million. With the recent growth and expansion of the company's in-house laboratory operations, salaries have increased approximately $0.6 million from the prior comparative period to $0.9 million. As a result of our recent growth and expansion, our net loss increased by $1.0 million, or 60% from the prior comparative period.

Liquidity and Capital Resources

We have experienced net losses of $2.6 million and $1.7 million for the three months ended March 31, 2010 and 2009, respectively. At March 31, 2010, we had $0.8 million in cash. We currently collect cash receipts from operations through both of our subsidiaries, Cord and Rain. Cord's cash flows from operations are not currently sufficient to fund operations in combination with these corporate expenses. During the period we have reduced our notes payable by $39,000.

Net cash used in operating activities increased approximately $1.0 million from the prior comparative period to $1.1 million. The increase was a result of the $0.8 million in start-up costs for stellacure, and $0.4 million in the issuance of stock for services. Net cash provided by financing activities increased approximately $1.1 million from the prior comparative period to $1.3 million. The largest contributor to this increase is the increase of proceeds from the issuance of notes payable. At the end of the period, cash and cash equivalents increased approximately $0.7 million from the prior comparative period to $0.8 million.

Since inception, we have financed cash flow requirements through the issuance of common stock and warrants for cash and services, and through loans and convertible debt. As we expand our operational activities, we likely will continue to experience net negative cash flows from operations and we will be required to obtain additional financing to fund operations through equity, debt and/or convertible debt offerings to the extent necessary to provide working capital. Financing may not be available, and, if available, it may not be available on acceptable terms. Should we secure such financing, it could have a negative impact on our financial condition and our shareholders. The sale of debt would, among other things, adversely impact our balance sheet, increase our expenses and increase our cash flow requirements. The sale of equity could, among other things, result in dilution to our shareholders. If our cash flows from operations are significantly less than projected, then we would either need to cut back on our budgeted spending, look to outside sources for additional funding or a combination of the two. If we are unable to access sufficient funds when needed, obtain additional external funding or generate sufficient revenue from the sale of our products, we could be forced to curtail or possibly cease operations.

In October 2009, the Company signed a credit line Promissory Note for $1.05 million with JMJ Financial bearing a one-time interest rate of 10%, and maturing in October, 2012. The Company has drawn down $0.9 million since inception under the credit line, with no amount being converted into common shares of the Company to date.

In January 2010, the Company signed two credit line Promissory Notes for $1.5 million each with JMJ Financial bearing one-time interest rates of 10%, and maturing in January, 2013. The Company has drawn down a total of $0.5 million since inception under these credit lines, with no amount being converted into common shares of the Company todate.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Disclosure not applicable to smaller reporting companies.

ITEM 4T. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

It is management's responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the "Exchange Act"). Our management, including our chief executive officer and our chief financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2010. Following this review and evaluation, management collectively determined that our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to management, including our chief executive officer, our chief operations officer, and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

The deficiency in our disclosure controls and procedures is related to a lack of segregation of duties due to the size of the accounting department and the lack of experienced accountants due to the limited financial resources of the Company. We hired an accountant in September 2009, and we expect his familiarization with the Company will enhance our disclosure controls. We are actively seeking additional financing to be able to afford to hire more accounting staff in an effort to remediate this lack of segregation of duties.

Changes in Internal Control over Financial Reporting

There were no significant changes in the Company's internal controls over financial reporting or in other factors that could significantly affect these internal controls subsequent to the date of their most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

PART II. - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

NONE

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

NONE

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4. RESERVED

ITEM 5. OTHER INFORMATION

NONE

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

The following exhibits are filed as part of this Form 10-Q.

3.0	Amended and Restated Articles of Incorporation of Cord Blood American, Inc. (1)

3.1	Amended and Restated Bylaws of Cord Blood America, Inc. (1)

10.1	Waiver Letter, dated May 22, 2008, by and among the Company and Enable Growth Partners LP, Enable Opportunity Partners LP and Pierce Diversified Strategy Master Fund LLC, ena. (2)

10.2	Fourth Amendment to Securities Purchase Agreement, dated June 3, 2008, by and among CorCell, Ltd., the Company, Career Channel, Inc., a Florida corporation d/b/a Rainmakers International, and Shelter Island Opportunity Fund, LLC. (2)

10.3	Form of Common Stock Purchase Warrant to Purchase Shares of Common Stock of the Company. (2)

10.4	Securities Purchase Agreement, dated as of June 27, 2008, by and between the Company and Tangiers Investors, LP (3)

10.5	Registration Rights Agreement, dated as of June 27, 2008, by and between the Company and the Tangiers Investors, LP. (3)

10.6	Form of Lock-Up Agreement. (3)

10.7	Stock Purchase Agreement with Optimus Capital Partners, LLC, dated as of August 3, 2009. (4)

10.8	1.3 Million Dollar Secured & Collateralized Convertible Promissory Note, dated May 18, 2009. (5)

10.9	Agreement to Acquire 138,712 Series B Shares (the Shares) in stellacure GmbH, a German Limited Liability Company. (6)

10.10

License Agreement with AXM Pharma, Inc.,

10.11

Lease for Las Vegas facility (7)

31.1	Certification of the registrant's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

31.2	Certification of the registrant's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

32.1	Certification of the Company's Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)

———————

(1) Filed as an exhibit to Registration Statement on Form 10-SB filed on May 6, 2004.

(2) Filed as an exhibit to Current Report on Form 8-K filed on June 3, 2008.

(3) Filed as an exhibit to Current Report on Form 8-K filed on July 3, 2008.

(4) Filed as an exhibit to Current Report on Form 8-K filed on August 3, 2009.

(5) Filed as an exhibit to Current Report on Form 8-K filed on May 18, 2009.

(6) Filed as an exhibit to Current Report on Form 8-K filed on March 29, 2010.

(7) Filed as an exhibit to Current Report on Form 10-K filed on March 31, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CORD BLOOD AMERICA, INC.

	By:	/s/ Matthew L. Schissler
		Matthew L. Schissler
		Chairman and Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer)
Date: May 20, 2010

Attached files

Stock widget

Investing forum

CBA Florida, Inc. Reports